CA2367108A1 - Methode utilisee pour inhiber une proteine chaperonne - Google Patents

Methode utilisee pour inhiber une proteine chaperonne Download PDF

Info

Publication number
CA2367108A1
CA2367108A1 CA002367108A CA2367108A CA2367108A1 CA 2367108 A1 CA2367108 A1 CA 2367108A1 CA 002367108 A CA002367108 A CA 002367108A CA 2367108 A CA2367108 A CA 2367108A CA 2367108 A1 CA2367108 A1 CA 2367108A1
Authority
CA
Canada
Prior art keywords
protein
client
coumarin
polypeptide
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002367108A
Other languages
English (en)
Inventor
Monica G. Marcu
Leonard M. Neckers
Theodor W. Schulte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367108A1 publication Critical patent/CA2367108A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne une méthode utilisée pour empêcher une protéine chaperonne de se fixer à sa protéine client ou à son polypeptide client. La méthode implique de mettre en relation un coumarinique ou un dérivé de coumarinique avec une protéine chaperonne, de telle sorte que le coumarinique ou le dérivé de coumarinique se fixe sur la protéine chaperonne, empêchant ainsi la protéine chaperonne de se fixer sur sa protéine client ou son polypeptide client.
CA002367108A 1999-03-12 2000-03-10 Methode utilisee pour inhiber une proteine chaperonne Abandoned CA2367108A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12413599P 1999-03-12 1999-03-12
US60/124,135 1999-03-12
PCT/US2000/006482 WO2000053169A2 (fr) 1999-03-12 2000-03-10 Methode utilisee pour inhiber une proteine chaperonne

Publications (1)

Publication Number Publication Date
CA2367108A1 true CA2367108A1 (fr) 2000-09-14

Family

ID=22412989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367108A Abandoned CA2367108A1 (fr) 1999-03-12 2000-03-10 Methode utilisee pour inhiber une proteine chaperonne

Country Status (5)

Country Link
EP (1) EP1161231A2 (fr)
JP (1) JP2003523313A (fr)
AU (1) AU776652B2 (fr)
CA (1) CA2367108A1 (fr)
WO (1) WO2000053169A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
EP1387678A1 (fr) * 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Composes inhibant hsp90 et stimulant hsp70 et hsp40, utiles pour prevenir ou traiter des maladies associees a l'agregation de proteines et a la formation d'amyloides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (fr) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibiteurs de protéine de choc thermique (HSP90) extracellulaire
CN100567242C (zh) * 2003-06-27 2009-12-09 协和发酵麒麟株式会社 Hsp90家族蛋白质阻断剂
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US7608594B2 (en) * 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
WO2010055929A1 (fr) * 2008-11-14 2010-05-20 国立大学法人京都大学 Nouveau peptide chimérique anti-cancer ciblant hsp90
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
CN101942017B (zh) 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors

Also Published As

Publication number Publication date
EP1161231A2 (fr) 2001-12-12
WO2000053169A2 (fr) 2000-09-14
AU3740600A (en) 2000-09-28
AU776652B2 (en) 2004-09-16
WO2000053169A8 (fr) 2001-01-11
JP2003523313A (ja) 2003-08-05

Similar Documents

Publication Publication Date Title
AU776652B2 (en) Method of inhibiting a chaperone protein
Grem et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
Henry et al. Flavone antagonists bind competitively with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation
Zhou et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells
Gupta et al. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
Cardozo et al. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation
Fu et al. Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro
US9114126B2 (en) Na/K-ATPase ligands, ouabain antagonists, assays and uses thereof
Zhang et al. Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner
Holstein et al. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis
Hamdan et al. Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176
Elia et al. Inhibition of HSP70 expression by calcium ionophore A23187 in human cells: an effect independent of the acquisition of DNA-binding activity by the heat shock transcription factor
Cleary et al. Effects of amphotericin B and caspofungin on histamine expression
US8586626B2 (en) Metabolites of wortmannin analogs and methods of using the same
Lei et al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments
Hirasawa et al. Pharmacological analysis of the inflammatory exudate-induced histamine production in bone marrow cells
KR20090053504A (ko) 피리미딘-2,4,6-트라이온 유도체를 함유하는 Ｈｓｐ９０억제제 및 이를 이용한 항암제
Gowans et al. Ophiobolin A covalently targets complex IV leading to mitochondrial metabolic collapse in cancer cells
Sondhauss Cellular effects of gliotoxin: Evaluation of a proteomic, isotope-based method to detect reactive cysteines
Li et al. Pharmacokinetics and metabolism of C hf197, a ligustrazine derivative, in rats
Ye et al. Total glucosides of paeony alleviates cGAS-STING-mediated diseases by blocking the STING-IRF3 interaction
Jin et al. Prolyl 4-hydroxylase alpha-2 directly activates mTOR kinase
Etman et al. Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Kristiansen The Effect of Structural Differences in PLX3397 and DCC-3014 on CSF1R Affinity and Pharmaceutical Properties: A Comparative Study
Bakaryan et al. Adenosine deaminase–A target for new piperazine derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead